Nello Mainolfi - 01 Mar 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 15:31:27 UTC
Previous filing
08 Dec 2022
Next filing
08 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +450,000 $0.000000 450,000 01 Mar 2023 Common Stock 450,000 $32.07 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.